Compare Enveric Biosciences Inc (ENVB) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Philip Morris International Inc. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Philip Morris International Inc. trades at $201.19 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 45955.9× Enveric Biosciences Inc's market cap, and Philip Morris International Inc. pays a 3.19% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Philip Morris International Inc. for 85 Days on average.
| ENVB | PM | |
|---|---|---|
Market Cap | $6.80M | $312.50B |
Volume | 64,867 | 5,517,172 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $201.19 |
52-Week Low | $1.27 | $144.33 |
Typical Hold Time | 14 Days | 85 Days |
Enterprise Value | -$1.49M | $355.62B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.52, up 1.67% with a bearish technical outlook despite recent earnings beats. The company shows no revenue but has improved quarterly EPS performance, with Q4 2025 turning positive. Analyst sentiment is bullish with 75% buy ratings, while technical indicators show selling pressure with 15 sell signals versus 1 buy.
Investment outlook remains speculative given negative profitability metrics and zero revenue, though patent developments and FDA guidance provide potential catalysts. Key risks include cash burn and clinical trial outcomes, while institutional support through financing offers near-term stability.
Philip Morris International (PM) trades at $200.5, up 4.05% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, and revenue growth is robust, driven by smoke-free products like IQOS and ZYN. The stock is near its pivot point of $200, with support at $197 and resistance at $203. Cash flow trends show improving operational performance, though debt levels remain elevated.
The outlook is positive due to earnings momentum and smoke-free product expansion, but risks include regulatory pressures and high valuation. Wall Street consensus is bullish with a $212.17 price target, suggesting upside potential. Investors should weigh growth prospects against macroeconomic and industry-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
